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Abstract 
Background: Ultrafiltration is a method used to achieve diuresis in acute decompensated 
heart failure (ADHF) when there is diuretic resistance but its efficacy in other settings is 
unclear.  We therefore conducted a systematic review and meta-analysis to evaluate the use 
of ultrafiltration in ADHF.   
Methods: We searched MEDLINE and EMBASE for studies which evaluated outcomes 
following filtration compared to diuretic therapy in ADHF.  The outcomes of interest were 
body weight change, change in renal function, length of stay, frequency of rehospitalization, 
mortality and dependence on dialysis.  We performed random effects meta-analyses to pool 
studies that evaluated the desired outcomes and assessed statistical heterogeneity using the I
2 
statistic.  
Results: A total of 10 trials with 857 participants (mean age 68 years, 71% male) compared 
filtration to usual diuretic care in ADHF. 9 studies evaluated weight change following 
filtration and the pooled results suggest a decline in mean body weight -1.8 95%CI -4.68-
0.97) kg.  Pooled results showed no difference between the filtration and diuretic group in 
change in creatinine or estimated glomerular filtration rate.  The pooled results suggest longer 
hospital stay with filtration (mean difference 3.70 95%CI -3.39-10.80) days) and a reduction 
in heart failure hospitalization (RR 0.71 95%CI 0.51-1.00)) and all-cause rehospitalization 
(RR 0.89 95%CI 0.43-1.86)) compared to the diuretic group. Filtration was associated with a 
non-significant greater risk of death compared to diuretic use (RR 1.08 95%CI 0.77-1.52).  
Conclusions: There is insufficient evidence supporting routine use of ultrafiltration in acute 
decompensated heart failure.   
 
Keywords: heart failure; meta-analysis; systematic review; ultrafiltration; diuretics  
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Introduction 
Acute decompensated heart failure (ADHF) accounts for nearly 1 million 
hospitalizations worldwide.[1]  ADHF is a blanket term covering a heterogeneous group of 
patients sharing a common clinical presentation of symptoms and signs of congestion or 
‘fluid overload.’  Diuretics have been the treatment option of choice for congestion for 
decades - irrespective of any clinical differences in presentation of ADHF.  Diuretic 
prescriptions are thought to reduce severe congestion slowly and therefore contribute to 
prolonged hospitalizations in these patients.  In addition, their use may also be complicated 
by electrolyte disturbances and some patients may become refractory to their use. 
Ultrafiltration, using either extracorporeal hemodialysis circuits or peritoneal 
dialysis,[2] is a recognized method for mechanical fluid management in patients with renal 
failure and has also been proposed as a therapeutic intervention to optimise fluid management 
in patients with decompensated heart failure.  Several studies have evaluated the efficacy of 
extracorporeal ultrafiltration compared to intravenous diuretics among decompensated 
patients without diuretic resistance and the results are inconsistent.[3-6] 
In view of the inconsistent evidence and the emergence of new studies we conducted 
a systematic review and meta-analysis to determine whether reported trials compared the 
efficacy of ultrafiltration with diuretics alone and if any patient groups more likely to benefit 
or be harmed by ultrafiltration compared to diuretics. 
 
Methods 
 We selected studies that investigated outcomes among patients with ADHF who were 
treated with either ultrafiltration or intravenous diuretics.  There was no restriction on 
whether patients had diuretic resistance but where available, information about the definition 
and prevalence of diuretic resistance was collected from each included study.  The outcomes 
of interest were weight change, change in creatinine and/or change in estimated glomerular 
filtration rate, length of stay, hospitalization, mortality and dialysis dependence.  Included 
studies had to evaluate a group managed with ultrafiltration compared to an intravenous/oral 
diuretics group.  There was no restriction based on phenotype or definition of heart failure, or 
language of study report but we only included randomized trials. 
 We searched MEDLINE and EMBASE using OVID SP with no date or language 
restriction in March 2016.  The exact free search terms were: (furosemide or bumetanide or 
diuretic or diuresis) AND (hemodialysis or haemodialysis or dialysis or hemofiltration or 
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haemofiltration or ultrafiltration or aquapheresis) AND (heart failure or cardiac failure or left 
ventricular impairment or cardiac insufficiency or cardiac decompensation). We checked the 
bibliography of relevant studies and reviews for additional studies that met the inclusion 
criteria. 
 Two reviewers (CSK and CWW) screened all titles and abstracts retrieved from the 
search for studies that met the inclusion criteria. The full manuscript of studies that 
potentially met the inclusion criteria was reviewed and the final decision to include or 
exclude studies was made with the other reviewers. Independent double extractions were 
performed by two reviewers (CSK and CWW) and data were collected on study design, year, 
country, number of participants, mean age, % male, participant inclusion criteria, protocol for 
filtration group, protocol for control group and results. 
 Quality assessment of the studies was conducted with consideration of random 
sequence generation, allocation concealment, blinding of participants and personnel, blinding 
of outcome ascertainment and complete outcome data. 
 We used RevMan V.5.3.5 (Nordic Cochrane Centre) to conduct random effects meta-
analysis using the inverse variance method for pooling log risk ratios (RRs). We used random 
effects because the studies were conducted in a wide range of settings in different 
populations, hence the need to take heterogeneity into account for the pooled effect estimate. 
Where possible, we chose to pool adjusted risk estimates from primary studies and when 
these data were not available, raw data were used to calculate unadjusted risk estimates.  
Change in creatinine were converted to mg/dl so that studies could be pooled using common 
units.  Where there were outcomes evaluated at multiple time points we chose to pool the 
results with the longest follow up because we wanted to establishthe longer term benefits of 
ultrafiltration compared to intravenous diuretics.  We used the I
2
 statistic to assess statistical 
heterogeneity. I
2
 Values of 30–60% represent moderate levels of heterogeneity.[7]  We 
performed sensitivity analysis where there was significant heterogeneity in an analysis 
(I
2
>60%). 
 
Results 
 The process of study selection is shown in Figure 1.  After removal of duplicates our 
search yielded 1,433 titles and abstracts.  After independent screening for study inclusion, the 
full manuscripts or conference abstracts of 57 studies were reviewed and 10 were retained for 
final inclusion in the review.[3-6,8-15] 
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 The description of the included studies is shown in Table 1.  There were 10 
randomized trials which took place in USA, Canada, Italy, Turkey and Russia between 2003 
to 2014.  There were a total of 857 participants (422 in filtration group and 435 in diuretic 
group).  The average age was 68 years and 71% were male. 
 The quality assessment of included studies is shown in Table 2.  Random sequence 
generation was unclear in 6 studies.  Allocation concealment was upheld in 2 studies and 
none of the studies were blinded to participants and personnel.  The outcome assessment was 
blinded in 2 studies and 5 studies had complete outcome data. 
The description of the population, filtration and diuretic protocol and results are 
shown in Table 3 and Table 4.  Most studies reported patients who had ADHF in NYHA 
class III to IV.  A variety of filtration methods and protocols were used and the diuretic 
regimen was not consistent across the studies.  None of the studies recorded any definition for 
diuretic resistance nor evaluate its prevalence in the study cohort. 
 A total of 9 studies evaluated weight change and the pooled results suggest a decline 
in body weight following filtration compared to diuretics, mean difference -1.86 95%CI -4.68 
to 0.97 kg, 646 participants, I
2
=98% (Figure 2). Exclusion of Tabekiyrian 2010 study reduced 
the heterogeneity from 98% to 55%.  After exclusion of this study the results suggested a 
significant decrease in body weight with ultrafiltration (mean difference -1.12 95%CI -2.01 to 
-0.22). 
Change in creatinine was reported in 8 studies and the pooled results showed no 
difference between the filtration and diuretic group (mean difference 0.01 95%CI -0.17 to 
0.19 mg/dl, 566 participants, I
2
=62%) (Figure 3a).  However, for estimated glomerular 
filtration rate there was a decline with filtration compared to diuretics but this was not 
significant (mean difference -2.77 95%CI -6.39 to 0.86 ml/min/m
2
, 4 studies, 303 
participants, I
2
=53%) (Figure 3b). 
Length of stay was reported in 3 studies and the pooled results suggest longer hospital 
stay with filtration compared to diuretics (mean difference 3.70 95%CI -3.39 to 10.80, 256 
participants, I
2
=99%) (Figure 4).  Exclusion of Tabekiyrian 2010 study reduced heterogeneity 
to 0% and the results are non-significant (mean diference 0.55 95%CI -0.54 to 1.64).  
In terms of rehospitalization, when compared to the diuretic group, there was a 
reduction with filtration for both heart failure hospitalization (RR 0.71 95%CI 0.51-1.00, 5 
studies, 669 participants, I
2
=38%) (Figure 5a) and all-cause rehospitalization (RR 0.89 
95%CI 0.43-1.86, 3 studies, 260 participants, I
2
=72%) (Figure 5b). Exclusion of Marenzi 
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2014 study reduced heterogeneity to 0% and the results are non-significant (mean difference 
1.25 95% CI 0.91 to 1.71).  
There were a total of 58 deaths out of 374 patients (15.5%) in the filtration group and 
55 deaths out of 386 patients (14.2%) in the diuretic group which yielded a pooled risk that 
favoured diuretic use (RR 1.08 95% CI 0.77 to 1.52, 760 participants, I
2
=0%) (Figure 6).   
2 studies evaluated dialysis dependence and there was a non-significant greater risk of 
dialysis dependence in the filtration group (2 dialysis patients out of 37 total patients, 5.4%) 
compared to the diuretic group (2 dialysis patients out of 49 total patients, 4.1%) (RR 1.44 
95% CI 0.03-59.72, 86 participants, I
2
=68%)(Figure 7). 
 
Discussion 
Our analysis suggests that ultrafiltration appears to be as efficacious as diuretics in 
terms of fluid loss and weight reduction without significant decline in renal function.  
However, the usual care received in both treatment arms is poorly defined and the timing of 
the evaluation of outcomes is highly variable. It is unclear if other interventions are the same 
in the usual care group such as the dose of loop diuretics, other diuretics (e.g. thiazides, etc), 
implementation of fluid restriction, the aggressiveness of fluid restriction, use of continuous 
positive airway pressure, use of intravenous nitrates and use of inotropes.  Furthermore, the 
timing of evaluation is important asthe amount of fluid loss, weight reduction and reduction 
in renal function after hospital stay or during follow up will depend on the aggressiveness of 
the usual care diuretic regime. 
A number of reviews have been previous published evaluating the efficacy of 
filtration compared to diuretic therapy.[16-22] Jain et al published the most recent review on 
ultrafiltration in acute heart failure.[22]  This review covered studies up until December 2015 
and included 7 randomized trials and found that ultrafiltration was associated with greater 
weight loss and fluid removal with significant reduction in heart failure hospitalization rate 
but no difference in mortality.  Our updated review with 3 additional studies found similar 
results except none of the results were statistically significant.  The authors do raise the 
important point that it remains to be clarified whether higher upfront cost associated with 
ultrafiltration may be offset by reduction in rate of heart failure readmission and resource 
utilization.  However, their study does not discuss important issues such as diuretic resistance 
which is an indication for ultrafiltration and the heterogeneity in methodology which is a 
limitation of included studies.  
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One challenge for this review was interpreting the findings in view of significant 
heterogeneity in study methodology.  First, some studies have been non-specific regarding 
the diuretic regimes and definition of diuretic resistance.  The prevalence of diuretic 
resistance will have a major effect on potential response in the control group.  The duration of 
ultrafiltration is further not specified  as using systems such as Aquadex have a longevity of 3 
days.  Consequently, it is likely that studies did not compare intravenous diuretics versus 
ultrafiltration but diuretics as part of usual care (control arm)  compared with a period of 
ultrafiltration and subsequent usual care  (intervention). The type of subsequent usual care is 
poorly specified and therefore deviations between the ‘control’ and ‘intervention’ groups 
after the period of ultrafiltration is not clear and potentially has major impact on overall 
patient outcomes. In the studies which evaluated length of stay in hospital it ranged from 6 to 
17 days in the ultrafiltration group and 5 to 19 days in the diuretic group.[5,8,9,15]  It is 
unclear why patients are admitted for a longer duration beyond the filtration period.  Ongoing 
hospitalisation after ultrafiltration may relate to complications of ultrafiltration, any 
differential in standard treatment such as the use of vasodilators, a recurrence of congestion 
requiring continued parenteral diuretic therapy or difficultyin social discharge arrangements 
related to increased frailty or dependence which were not in the comparative patient 
demographics.  High quality individual patient data would help clarify this issue further but is 
unavailable here.  Furthermore, future studies should document the ongoing treatment of 
patients who remain in hospital after substantial fluid removal following ultrafiltration.  This 
would then allow a true comparison of ultrafiltration (within a wider strategy of heart failure 
management) – the intervention – versus that of a usual strategy of ADHF management 
including diuretic use – the control arm. 
In addition to efficacy endpoints, it is important to consider the safety impact of 
ultrafiltration compared to diuretics.  Ultrafiltration is associated with potential vascular 
complications, pneumothorax and infections.  Heparinization is required for aquadex which 
could lead to bleeding complications but we did not find any evidence of increased adverse 
bleeding events with ultrafiltration.  In addition, ultrafiltration cannot be performed in all 
patient areas and may require a bed in a specialist unit with skilled nursing input.  However, 
most of the studies failed to report events that may be related to heparinization and the studies 
also are underpowered to evaluate these relatively uncommon events.  Nonetheless, it is 
important to consider the efficacy benefit as well as the risk of complications in selecting 
therapy for diuresis and many of the studies are underpowered to capture these complications. 
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Current evidence fails to identify any particular sub-groups that either benefit from or 
are harmed more by ultrafiltration in comparison to diuretics such as patients with cardiorenal 
syndrome. Congestion is believed to be one of the main drivers of cardiorenal syndrome.  A 
potential benefit of ultrafiltration over diuretics is that there may be preserved renal function 
while fluid is removed with ultrafiltration while diuretics may cause renal hypoperfusion.  In 
addition, theoretically, ultrafiltration may be more “gentle” in reducing congestion so that 
physiological compensatory mechanism can gradually compensate without sudden fluid 
shifts.  Another potential benefit of ultrafiltration includes a greater reduction of sodium load 
and removal of potentially vasoactive substances below the filter clearance of the ultrafilter 
e.g. in terms of the Aquadex to remove <65 Kda molecules. While these these theoretical 
advantages are attractive they do not appear to translate into clear clinical benefit.  
Nevertheless, identification of sub-groups of patients who may benefit is important to help 
guide real world practice should be explored in future studies. 
It has been suggested that ultrafiltration should be considered in diuretic resistance 
where there is persistent edema despite adequate diuretic therapy.[23] However, there is no 
definition of adequate diuretic therapy.  Diuretic resistance is multifactorial in etiology and 
could include lower than efficacious duretic dose. This was demonstrated in the CARRESS 
trial using incremental diuretic doses and inotropes adjusted to maintain urine output of 3 to 5 
litres per day.[4]  We would therefore recommend ultrafiltration be considered for patients 
exhibiting diuretic resistance following a clinical diuretic regime similar to that used in 
CARRESS.  
Based on the findings of the review we are in a position to propose a number of 
recommendations for future studies.  We would suggest that future trials consider 
comparisons of intravenous diuretics alone versus ultrafiltration alone for resolution of 
congestive symptoms. Also, another question worth exploring is whether ultrafiltation in 
addition to maintenance diuretic therapy is superior to maintance diuretic therapy alone.  
Therefore clinical trials should be designed so the clearly state which question they wish to 
address. Specific patient groups which may benefit from ultrafiltration, such as those with 
hypokalemia, hyponatremia, profound hypotension and diuretic resistance should be 
explored. While it is clear that diuretics should be used cautiously in hypokalemia, it is less 
straight forward for cases of hyponatremia. In this situation hyponatremia often reflects 
reduced free water excretion that can be ameliorated with ultrafiltration. With respect to 
patients with decompensated heart failure who have significant hypotension, many studies 
have excluded patients whose systolic blood pressure measured below 100 mmHg. However, 
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hypotension is commonly encountered in clinical practice and in such instances inotropes can 
be used to facilitate the concomitant use of diuretics to relieve hypervolemia, as was done in 
the CARRESS-HF trial.[4] Future studies should also clearly define diuretic resistance within 
their study population as this is a stronger indication for ultrafiltration as well as the extent of 
cardiorenal syndrome in the cohort. In addition, the effectiveness of the ultrafiltration to 
cause diuresis and the extent of improvement in cardiac function will depend on the filtration 
settings.  Important factors which need to be clarified include the system associated with best 
outcome, best types of filters, the optimal rate of filtration, duration of filtration procedure, 
the total extracorporeal blood volume and number of sessions.  For diuretic protocol, there 
are a variety of factors which might influence dose and aggressiveness of diuresis such as 
fluid status, patient symptoms and electrolyte disturbance. In addition, the studies do not 
really talk about the cost implications of ultrafiltration compared to diuretics which is an 
important consideration. 
This study has several strengths and limitations.  We were able to perform an updated 
review with more trials than any of the previous review (10 studies).  In addition, we were 
able to consider a variety of important outcomes such as change in body weight, renal 
function, length of stay as well as hard outcomes like mortality and rehospitalization.  
However, only 3 of the studies were adequately powered and the most recent high quality 
ultrafiltration trial, AVOID-HF, was terminated early by the sponsor.  The termination took 
place because slower-than-projected study enrollment (study recruited 224 patients when 810 
were planned) and termination was in no way related to signals of futility or safety concerns.  
While were were able to include the results of this trial it is clear it also lacks statistical power 
for the the primary endpoint.  While the trial had be terminated early it remains the largest 
trial to date. The withdrawal of sponsors from the trial designed to answer some of these 
questions demonstrates the necessity for interventions and trials to be clinically independent 
of the providers of trial funding. In addition, the methodological quality of the smaller studies 
in general were poor and none of the studies blinded participants and personnel to the group 
which they were randomized to.    
In conclusion, there is insufficient evidence to suggest routine use of ultrafiltration in 
any setting of acute decompensated heart failure.  While we show evidence that it is superior 
to intravenous diuretics in terms of weight loss and heart failure admissions, as diuretics are 
inexpensive, there are a few arguments to consider routine ultrafiltration over diuretics.  
While ultrafiltration can remove 6-9 kilograms over a few days compared to parenteral 
diuretics can remove up to a few kilogram a day, ultrafiltration requires anticoagulation and 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
admission to specialist unit for close monitoring which is expensive.[4]  Theoretically, 
ultrafiltration may require less time to achieve diuresis compared to diuretics, though current 
evidence suggests no difference in length of stay.  More studies are needed to characterize 
whether certain cases of acute heart failure will benefit from ultrafiltration at an early stage 
and the best ultrafiltration protocol. 
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Table 1: Study design and participant characteristics 
 
Study ID Study Design; 
Country; Year 
Sample size; 
Filtration group; 
Diuretic group 
Mean 
age 
 
% 
Male 
Participants 
Bart 2005 (RAPID-CHF) RCT; USA; 2003-
2004. 
40; 20; 20 68.5 70 Congestive heart failure . 
Bart 2012 (CARRESS-HF) RCT; 
USA/Canada; 
2008-2012. 
188; 94; 94 67.5 75 Acute decompensated heart 
failure with worsened renal 
function. 
Chung 2014 RCT; USA; 
Unclear. 
16; 8; 8 71.5 94 Acute decompensated heart 
failure. 
Costanzo 2007 & Rogers 
2008 & Costanzo 2010 
(UNLOAD) 
RCT; USA; 2004-
2005. 
200; 100; 100 63 69 Acute decompensated heart 
failure. 
Costanzo 2016 (AVOID-
HF) 
RCT; USA; 2013-
2014. 
221; 110; 111 67 71 Acute decompensated heart 
failure. 
Giglioli 2011 
(ULTRDISCO) 
RCT; Italy; 
Unclear. 
30; 15; 15 69 87 Decompensated heart failure. 
Hanna 2012 RCT; USA; 2003-
2006. 
36; 19; 17 60 80.6 Acute decompensated heart 
failure admitted to intensive 
care unit. 
Marenzi 2014 (CUORE) RCT; Italy; 2006-
2010. 
56; 27; 29 74  23 Congestive heart failure.  
Seker 2016 RCT; Turkey; 
Unclear. 
30; 10; 20 67 63 Heart failure with evidence of 
right ventricular failure.  
Tabakyian 2010 RCT; Russia; 
Unclear. 
40; 19; 21 30-82 
years. 
78 Congestive heart failure. 
RCT=randomized controlled trials 
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Table 2: Quality assessment 
Study ID 
 
Random sequence 
generation 
 
Allocation 
concealment 
Blinding of 
participants 
and personnel 
Blinding of 
outcome 
ascertainment 
Complete outcome 
data 
Bart 2005 (RAPID-
CHF) 
Unclear. No, no 
allocation 
concealment. 
No, unblinded. No. No, 2 patients did not 
undergo the 
ultrafiltration. 
Bart 2012 (CARRESS-
HF) 
Web-based system. No, no 
allocation 
concealment. 
No, unblinded. No. No, 2 patients had 
missing data. 
Chung 2014 Unclear. No, no 
allocation 
concealment. 
No, unblinded. No. Yes. 
Costanzo 2007 & 
Rogers 2008 & 
Costanzo 2010 
(UNLOAD) 
Unclear. No, no 
allocation 
concealment. 
No, unblinded. No.  Unclear. 
Costanzo 2016 
(AVOID-HF) 
Central web-based 
system. 
No, no 
allocation 
concealment. 
No, unblinded. Yes, an 
independent Study 
End-point 
Committee. 
No, 9 patients lost to 
follow up and 10 
patients withdrew 
participation.  
Giglioli 2011 
(ULTRADISCO) 
Unclear. No, no 
allocation 
concealment. 
No, unblinded. No.  Yes. 
Hanna 2012 Randomized in 
blocks of 4 and 2 
within 2 strata 
based on GFR. 
Yes, random 
sealed 
envelope. 
No, unblinded. No.  No, 3 patients 
withdrew 
participation. 
Marenzi 2014 
(CUORE) 
Computer-
generated. 
Yes, random 
sealed 
envelope.  
No, unblinded. Yes, blinded 
physicians. 
No, 2 patients were 
not followed up. 
Seker 2016 Unclear No, no 
allocation 
concealment. 
No, unblinded. No. Yes. 
Tabakyian 2010 Unclear No, no 
allocation 
concealment. 
No, unblinded. No. Yes. 
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Table 3: Protocols for filtration and control group 
Study ID Protocol for filtration group: Protocol for control group 
Bart 2005 (RAPID-CHF) System 100 for an 8h course with fluid removal rate 
determined by the attending physician (<500ml/h). 
Not defined. 
Bart 2012 (CARRESS-
HF) 
Aquadex System 100 performed at a fluid-removal 
rate of 200ml/h.  
Doses of diuretics adjusted to maintain a 
urine output of 3 to 5L/day. 
Chung 2014 Aquadex 100 system with a target weight to be 
removed established by the heart failure service with 
mean UF rate was 162ml/h. 
IV furosemide  with mean daily dose of 212 
mg. 
Costanzo 2007 & Rogers 
2008 & Costanzo 2010 
(UNLOAD) 
Aquadex System 100 with flow between 10-
40mL/min and total blood volume of 33mL. The 
duration and rate (<500ml/h) of fluid removal were 
decided by treating physician. 
At least twice the pre-hospitalization dose of 
diuretics. 68 patients received IV diuretics as 
bolus injections and 32 as continuous 
infusion. 
Costanzo 2016 (AVOID-
HF) 
Aquadex Flex Flow System with adjustment of 
therapy according to patient's response. 
The diuretic protocol permit adjustment of 
therapy according to patient's response. 
Giglioli 2011 
(ULTRADISCO) 
M 100 PRESET PRISMA filter and a blood flow 
rate of 150mL/h. Continuous UF technique with 
initial rate of 100-300mL/h. This was adjusted 
according to response.  
Continuous IV furosemide at an initial dose 
of 250mg/24h. This was reduced or increased 
according to patient response to maximum 
dose of 500mg/24h. 
Hanna 2012 NxStage System One with initial rate was 400mL/h 
for 6 hours then decreased to 200mL/h. 
IV diuretics according to treating clinician. 
Marenzi 2014 (CUORE) Peristaltic pump/polysulphone filter and a blood 
flow from 40-100mL/min, and a blood volume of 
100mL. Duration and filtration rate (100-500mL/h) 
varied with 1 or 2 sessions.  
IV loop diuretics by experienced heart failure 
cardiologists according to guideline 
recommendations. 
Seker 2016 UF with max rate of 500cc/h and duration 
determined by clinician. The rate of blood flow was 
set to 50-100mL/min. UF terminated if satisfactory 
clinical decongestion. 
Maximum tolerable dose of IV diuretics as a 
bolus or continuous infusion. 
Tabak'ian 2010 Dialyzer Diacap LO filter slow continuous filtration 
with 90 ml and rate 9.8 ml/h/mmHg. Diacap HI PS 
continuous veno-venous hemofiltration with 68 ml 
and rate 42 ml/h/mmHg. 
Given furosemide doses ≥80mg/day and then 
furosemide or torasemide tablets. 
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Table 4: Study results 
Study ID Population Results 
Bart 2005 (RAPID-CHF) CHF. Change in weight (kg): -2.5±1.2 vs -1.86±1.2. Mortality at 30 days: 1/20 vs 0/20. 
Bart 2012 (CARRESS-HF) ADHF.  Change in weight (kg): -5.7±3.9 vs -5.5±5.1. Change in creatinine at 96 h (mg/dl): 
+0.23±0.70 vs -0.04±0.53. Change in GFR at 96 h: +0.93±14.60 vs +1.67±10.94. All-
cause hospitalization: 46/94 vs 37/94. Heart failure hospitalization: 23/94 vs 24/94. 
Mortality: 16/94 vs 13/94. 
Chung 2014 ADHF. Change in weight (kg): -6.5±3.6 vs -7.4±3.3. Change in creatinine (mg/dl): -
0.13±0.46 vs 0.12±0.46. Length of stay (days): 6.58±1.33 vs 5.83±3.25. All-cause 
hospitalization: 30-day 3/8 vs 3/8, 90-day 4/8 vs 3/8. 
Costanzo 2007 & Rogers 
2008 & Costanzo 2010 
(UNLOAD) 
ADHF. Change in weight (kg): -5.0±3.1 vs -3.1±3.5. Change in creatinine (mg/dl): 0.1±0.4 vs 
0.1±0.4. Change in GFR: -3.4±7.7 vs -3.6±11.5. 
Length of stay (days): 6.3±4.9 vs 5.8±3.8. Mortality: 9/94 vs 11/95. Heart failure 
hospitalization at 90 days: 16/89 vs 28/87.  
Costanzo 2016 (AVOID-
HF) 
ADHF. Change in weight (kg): -7.9±5.8 vs -7.5±6.5. Changes in serum creatinine at discharge 
(mg/dl): 0.12±0.42 vs 0.12±0.50. Heart failure hospitalization: 30 days 10/110 vs 
22/111, p=0.034, 90 days 27/105 vs 39/108. Mortality at 90 days: 17/110 vs 14/111. 
Giglioli 2011 
(ULTRADISCO) 
ADHF. Change in weight (kg): -9.1±1.7 vs -6.9±1.8. Change in creatinine (mg/dl): -
0.55±0.75 vs 0.07±0.63. 
Hanna 2012 ADHF. Change in weight (kg): -4.7±3.5 vs -1.0±2.5. Change in creatinine (mg/dl): 0.2±0.7 vs 
0±0.8. Heart failure hospitalization at 90 days: 8/19 vs 6/17. Mortality: 4/19 (21.1%) 
vs 4/17 (23.5%). 
Marenzi 2014 (CUORE) CHF. Change in weight (kg): -7.5±5.6 vs -7.9±9.0. Change in creatinine (mg/dl):0.1±0.63 
vs 0±0.7. Change in GFR at discharge: -3±21 vs -3±27. CHF hospitalization: 1 year 
4/27 vs 14/29. All-cause hospitalization: 1 year 7/27 vs 17/29. Mortality at 1 year: 
7/27 vs 11/29.  Chronic dialysis: 0/27 vs 2/29. 
Seker 2016 CHF. Mortality: 4/10 vs 2/20. Haemodialysis during follow up: 2/10 vs 0/20. 
Tabak'ian 2010 CHF. Change in weight (kg): -10.1±1.08 vs -1.92±0.83. Change in GFR -1.16±3.23 vs 
4.44±3.68. Length of stay (days): 17.26±1.43 vs 7.52±1.02. 
UF=ultrafiltration, HF=heart failure, CHF=congestive heart failure, IV=intravenous, GFR=glomerular 
filtration rate. 
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Highlights 
 The role of ultrafiltration in acute decompensated heart failure is unclear. 
 Ultrafiltration is as efficacious as diuretics for fluid loss via weight reduction. 
 Ultrafiltration is not associated without significant decline in renal function. 
 Ultrafiltration reduces heart failure hospitalization. 
 Routine ultrafiltration in acute decompensated heart failure is not recommended. 
